US Patent
US8372995 — Crystalline solid forms of tigecycline and methods of preparing same
Formulation · Assigned to Wyeth LLC · Expires 2030-10-08 · 4y remaining
Vulnerability score
53/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects crystalline solid forms of tigecycline, specifically Forms I, II, III, IV, and V, and methods for preparing them.
USPTO Abstract
Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
Drugs covered by this patent
- Tygacil (TIGECYCLINE) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.